Safety assessment of the Yeast Extract containing nicotinamide mononucleotide (NMN)

Safety assessment of the Yeast Extract containing nicotinamide mononucleotide (NMN) - Safety of Yeast Extract containing NMN

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039527

Enrollment

Registered

2020-02-18

Start date

2019-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

Test Food 1: 10% Yeast extract containing NMN 2.5 g/day (24 tablets twice at morning and evening) for 12 weeks Test Food 2: placebo (Dextran) at 2.5 g/day for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Healthy Japanese volunteer with age between 20 and 65 2. Qualified person judged by medical doctor based on the results of clinical laboratory test: TG, LDL-cholesterol, fasting glucose, HbA1c, AST, ALT, gamma-GTP, Serum amylase, Creatinine

Exclusion criteria

Exclusion criteria: 1. Person with past treatment history of malignant tumor, heart failure, or myocardial infarction. 2. Person currently under treatment for atrial fibrillation, arrhythmia, hepatic dysfunction, renal dysfunction, cerebrovascular disorder, rheumatism, diabetes, dyslipidemia, hypertension, or other chronic diseases.3. Person with medication (including Kampo medicine). 4. Person with allergy against medicine or the test food 5. Pregnant, unwilling to practice contraception during the study, or lactating female 6. Person who is not judged as not qualified by the medical doctor.

Design outcomes

Primary

Measure	Time frame
Safety assessment (1) Physical measurements height, weight, body fat percentage, BMI, systolic blood pressure, diastolic blood pressure, heart rate (2) Blood test hematology: white blood cell count, red blood cell count, hemoglobin, Hematocrit, platelet count, MCV, MCH, MCHC b. Biochemical tests: TG, total cholesterol, LDL-cholesterol, HDL-cholesterol, free fatty acid, acetoacetic acid, 3-hydroxyacetic acid, total ketone body , lipoprotein (a), glucose, HbA1c, insulin, AST , AL T, gamma-GTP, ALP, LDH, total protein, albumin, uric acid, urea nitrogen, creatinine, sodium, chloride, potassium, calcium, inorganic phosphorus, magnesium (3) Urine testing Sugar, protein, urobilinogen, ketone body, pH, specific gravity, occult blood reaction, bilirubin, sediment (when protein is positive) (4) Diary	—

Measure

Time frame

Safety assessment (1) Physical measurements height, weight, body fat percentage, BMI, systolic blood pressure, diastolic blood pressure, heart rate (2) Blood test hematology: white blood cell count, red blood cell count, hemoglobin, Hematocrit, platelet count, MCV, MCH, MCHC b. Biochemical tests: TG, total cholesterol, LDL-cholesterol, HDL-cholesterol, free fatty acid, acetoacetic acid, 3-hydroxyacetic acid, total ketone body , lipoprotein (a), glucose, HbA1c, insulin, AST , AL T, gamma-GTP, ALP, LDH, total protein, albumin, uric acid, urea nitrogen, creatinine, sodium, chloride, potassium, calcium, inorganic phosphorus, magnesium (3) Urine testing Sugar, protein, urobilinogen, ketone body, pH, specific gravity, occult blood reaction, bilirubin, sediment (when protein is positive) (4) Diary

—

Secondary

Measure	Time frame
Assessment the NAD-related metabolites in blood Blood NAD,NMN,nicotinamide,NA,NR,NAR,NAMN,NAAD	—

Countries

Japan

Contacts

Public ContactNakagawa Takashi

University of Toyama Faculty of Medicine, Department of Molecular and Medical Pharmacology

nakagawa@med.u-toyama.ac.jp076-434-7262

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026